Inovio Pharmaceuticals annual shares outstanding
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Inovio Pharmaceuticals Shares Outstanding History (INO)
Inovio Pharmaceuticals reported 69.0M shares outstanding at the end of fiscal 2025.
View full Inovio Pharmaceuticals company overviewInovio Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 69.0M | 32.9M | +91.13% |
| 2024 | 2024-12-31 | 36.1M | 13.3M | +58.38% |
| 2023 | 2023-12-31 | 22.8M | 1.7M | +8.07% |
| 2022 | 2022-12-31 | 21.1M | 19.6M | +1297.68% |
| 2021 | 2021-12-31 | 1.5M | 211,937.912 | +16.34% |
| 2020 | 2020-12-31 | 1.3M | 593,443.896 | +84.34% |
| 2019 | 2019-12-31 | 703,611.697 | 28,705.232 | +4.25% |
| 2018 | 2018-12-31 | 674,906.465 | 47,676.328 | +7.60% |
| 2017 | 2017-12-31 | 627,230.137 | 113,115.908 | +22.00% |
| 2016 | 2016-12-31 | 514,114.229 | 12,803.193 | +2.55% |
| 2015 | 2015-12-31 | 501,311.035 | 79,668.377 | +18.89% |
| 2014 | 2014-12-31 | 421,642.658 | 56,676.344 | +15.53% |
| 2013 | 2013-12-31 | 364,966.314 | 114,524.122 | +45.73% |
| 2012 | 2012-12-31 | 250,442.192 | 16,216.729 | +6.92% |
| 2011 | 2011-12-31 | 234,225.464 | 51,941.164 | +28.49% |
| 2010 | 2010-12-31 | 182,284.3 | — | — |
Inovio Pharmaceuticals quarterly shares outstanding
Q4.10
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 82.3M | 45.6M | +124.25% |
| Q1 2026 | 2026-03-31 | 69.8M | 33.1M | +90.25% |
| Q4 2025 | 2025-12-31 | 69.0M | 32.9M | +91.13% |
| Q3 2025 | 2025-09-30 | 53.6M | 27.5M | +105.63% |
| Q2 2025 | 2025-06-30 | 36.7M | 10.8M | +41.42% |
| Q1 2025 | 2025-03-31 | 36.7M | 13.3M | +56.92% |
| Q4 2024 | 2024-12-31 | 36.1M | 13.3M | +58.38% |
| Q3 2024 | 2024-09-30 | 26.1M | 24.2M | +1291.41% |
| Q2 2024 | 2024-06-30 | 26.0M | 24.1M | +1295.24% |
| Q1 2024 | 2024-03-31 | 23.4M | 21.5M | +1181.43% |
| Q4 2023 | 2023-12-31 | 22.8M | 1.7M | +8.07% |
| Q3 2023 | 2023-09-30 | 1.9M | 140,541.928 | +8.12% |
| Q2 2023 | 2023-06-30 | 1.9M | 142,780.176 | +8.31% |
| Q1 2023 | 2023-03-31 | 1.8M | 251,484.512 | +15.99% |
| Q4 2022 | 2022-12-31 | 21.1M | 19.6M | +1297.68% |
| Q3 2022 | 2022-09-30 | 1.7M | 271,573.782 | +18.60% |
| Q2 2022 | 2022-06-30 | 1.7M | 259,323.434 | +17.78% |
| Q1 2022 | 2022-03-31 | 1.6M | 119,234.338 | +8.21% |
| Q4 2021 | 2021-12-31 | 1.5M | 211,937.912 | +16.34% |
| Q3 2021 | 2021-09-30 | 1.5M | 297,340.93 | +25.57% |
| Q2 2021 | 2021-06-30 | 1.5M | 356,734.079 | +32.37% |
| Q1 2021 | 2021-03-31 | 1.5M | 440,231.353 | +43.46% |
| Q4 2020 | 2020-12-31 | 1.3M | 593,443.896 | +84.34% |
| Q3 2020 | 2020-09-30 | 1.2M | 475,379.238 | +69.14% |
| Q2 2020 | 2020-06-30 | 1.1M | 417,692.574 | +61.04% |
| Q1 2020 | 2020-03-31 | 1.0M | 333,067.401 | +48.99% |
| Q4 2019 | 2019-12-31 | 703,611.697 | 28,705.232 | +4.25% |
| Q3 2019 | 2019-09-30 | 687,542.663 | 31,749.453 | +4.84% |
| Q2 2019 | 2019-06-30 | 684,337.105 | 49,354.886 | +7.77% |
| Q1 2019 | 2019-03-31 | 679,822.533 | 50,181.656 | +7.97% |
| Q4 2018 | 2018-12-31 | 674,906.465 | 47,676.328 | +7.60% |
| Q3 2018 | 2018-09-30 | 655,793.21 | 28,998.363 | +4.63% |
| Q2 2018 | 2018-06-30 | 634,982.219 | 96,076.302 | +17.83% |
| Q1 2018 | 2018-03-31 | 629,640.877 | 111,607.101 | +21.54% |
| Q4 2017 | 2017-12-31 | 627,230.137 | 113,115.908 | +22.00% |
| Q3 2017 | 2017-09-30 | 626,794.847 | 113,344.517 | +22.08% |
| Q2 2017 | 2017-06-30 | 538,905.917 | 28,814.445 | +5.65% |
| Q1 2017 | 2017-03-31 | 518,033.776 | 16,374.146 | +3.26% |
| Q4 2016 | 2016-12-31 | 514,114.229 | 12,803.193 | +2.55% |
| Q3 2016 | 2016-09-30 | 513,450.33 | 12,397.323 | +2.47% |
| Q2 2016 | 2016-06-30 | 510,091.473 | 11,611.092 | +2.33% |
| Q1 2016 | 2016-03-31 | 501,659.63 | 80,016.973 | +18.98% |
| Q4 2015 | 2015-12-31 | 501,311.035 | 79,668.377 | +18.89% |
| Q3 2015 | 2015-09-30 | 501,053.007 | 81,375.819 | +19.39% |
| Q2 2015 | 2015-06-30 | 498,480.381 | 79,776.834 | +19.05% |
| Q1 2015 | 2015-03-31 | 421,642.658 | 4,890.359 | +1.17% |
| Q4 2014 | 2014-12-31 | 421,642.658 | 56,676.344 | +15.53% |
| Q3 2014 | 2014-09-30 | 419,677.188 | 59,371.357 | +16.48% |
| Q2 2014 | 2014-06-30 | 418,703.547 | 106,228.093 | +34.00% |
| Q1 2014 | 2014-03-31 | 416,752.299 | 104,481.179 | +33.46% |
| Q4 2013 | 2013-12-31 | 364,966.314 | 114,524.122 | +45.73% |
| Q3 2013 | 2013-09-30 | 360,305.831 | 118,452.572 | +48.98% |
| Q2 2013 | 2013-06-30 | 312,475.454 | 78,249.991 | +33.41% |
| Q1 2013 | 2013-03-31 | 312,271.12 | 78,045.657 | +33.32% |
| Q4 2012 | 2012-12-31 | 250,442.192 | 16,216.729 | +6.92% |
| Q3 2012 | 2012-09-30 | 241,853.259 | 20,989.951 | +9.50% |
| Q2 2012 | 2012-06-30 | 234,225.464 | 13,382.59 | +6.06% |
| Q1 2012 | 2012-03-31 | 234,225.464 | — | — |
| Q4 2011 | 2011-12-31 | 234,225.464 | 51,941.164 | +28.49% |
| Q3 2011 | 2011-09-30 | 220,863.308 | — | — |
| Q2 2011 | 2011-06-30 | 220,842.874 | — | — |
| Q4 2010 | 2010-12-31 | 182,284.3 | — | — |
Inovio Pharmaceuticals shares outstanding trends
Over the last five fiscal years, Inovio Pharmaceuticals's shares outstanding moved from 1.3M to 69.0M, a change of 67.7M. The latest reported quarter, Q2 2026, shows 82.3M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Inovio Pharmaceuticals source filings ↗Community posts
Inovio wins an $80.4 million judgment but warns collection may be limited
Inovio ($INO) announced a favorable judgment totaling approximately $80.4 million in its litigation against VGXI and GeneOne Life Science. The award comprises roughly $61.8 million in compensation and $18.7 million in legal fees and costs. ...
